Tango Therapeutics (TNGX) Return on Capital Employed (2021 - 2026)
Tango Therapeutics (TNGX) posted quarterly Return on Capital Employed of 29.17% for Q1 2026, up 2705.0% year-over-year from 1.04% in Q1 2025, and up 25.89% quarter-over-quarter from 39.36% in Q4 2025.
Tango Therapeutics (TNGX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Tango Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 29.17% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 2705.0% year-over-year to 29.17%; the TTM figure through Mar 2026 stood at 29.17% (up 2705.0% YoY), while the FY2025 annual figure was 33.13%, up 1218.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 29.17%, up from 39.36% in the prior quarter.
- The five-year high for Return on Capital Employed was 16.01% in Q1 2022, with the low at 72.79% in Q2 2025.
- The 5-year median for Return on Capital Employed is 33.74% (2023), against an average of 37.29%.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed plunged 3495 bps in 2025, then soared 2705 bps in 2026.
- Tango Therapeutics' Return on Capital Employed stood at 28.14% in 2022, then decreased by 10 bps to 30.9% in 2023, then slumped by 59 bps to 49.14% in 2024, then rose by 20 bps to 39.36% in 2025, then increased by 26 bps to 29.17% in 2026.
- Business Quant data shows TNGX's Return on Capital Employed at 29.17% in Q1 2026, 39.36% in Q4 2025, and 53.67% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | -18.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.56% |
| Mar 31, 2026 | -29.17% |
| Dec 31, 2025 | -39.36% |
| Sep 30, 2025 | -53.67% |
| Jun 30, 2025 | -72.79% |
| Mar 31, 2025 | -56.22% |
| Dec 31, 2024 | -49.14% |
| Sep 30, 2024 | -42.42% |
| Jun 30, 2024 | -37.85% |
| Mar 31, 2024 | -34.88% |
| Dec 31, 2023 | -30.90% |
| Sep 30, 2023 | -30.45% |
| Jun 30, 2023 | -33.74% |
| Mar 31, 2023 | -31.65% |
| Dec 31, 2022 | -28.14% |
| Sep 30, 2022 | -25.31% |
| Jun 30, 2022 | -22.19% |
| Mar 31, 2022 | -16.01% |
| Dec 31, 2021 | -12.26% |
| Sep 30, 2021 | -11.86% |